newsfilter
← Latest News
Business Wire·

Dicerna Announces Results for PHYOX™4, Single-Dose Study of Nedosiran in Primary Hyperoxaluria Type 3 (PH3)

– Study Met Primary Safety Endpoint; Nedosiran Shown to be Generally Safe and Well Tolerated in Patients With PH3 – – Although Trial Did Not Meet Prespecified Secondary Efficacy Endpoint, Data Showed Encouraging Trends in Urinary Oxalate Reduct